ERCC1 Isoform Expression and DNA Repair in Non–Small-Cell Lung Cancer-Reference-Cited by-同舟云学术

ERCC1 Isoform Expression and DNA Repair in Non–Small-Cell Lung Cancer

Published:2013-03-21 Issue:12 Volume:368 Page:1101-1110
ISSN:0028-4793
Container-title:New England Journal of Medicine
language:en
Short-container-title:N Engl J Med

Author:

Friboulet Luc,Olaussen Ken André,Pignon Jean-Pierre,Shepherd Frances A.,Tsao Ming-Sound,Graziano Stephen,Kratzke Robert,Douillard Jean-Yves,Seymour Lesley,Pirker Robert,Filipits Martin,André Fabrice,Solary Eric,Ponsonnailles Florence,Robin Angélique,Stoclin Annabelle,Dorvault Nicolas,Commo Frédéric,Adam Julien,Vanhecke Elsa,Saulnier Patrick,Thomale Jürgen,Le Chevalier Thierry,Dunant Ariane,Rousseau Vanessa,Le Teuff Gwénaël,Brambilla Elisabeth,Soria Jean-Charles

Publisher

Massachusetts Medical Society

Subject

General Medicine

Link

http://www.nejm.org/doi/pdf/10.1056/NEJMoa1214271

Cited by 318 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. L3MBTL1, a polycomb protein, promotes Osimertinib acquired resistance through epigenetic regulation of DNA damage response in lung adenocarcinoma;Cell Death & Disease;2024-09-04

2. ERCC1 and ERCC2 Polymorphisms Predict the Efficacy and Toxicity of Platinum-Based Chemotherapy in Small Cell Lung Cancer;Pharmaceutics;2024-08-25

3. Repression of PRMT activities sensitize homologous recombination-proficient ovarian and breast cancer cells to PARP inhibitor treatment;2024-07-17

4. Repression of PRMT activities sensitize homologous recombination-proficient ovarian and breast cancer cells to PARP inhibitor treatment;2024-07-17

5. Cisplatin in the era of PARP inhibitors and immunotherapy;Pharmacology & Therapeutics;2024-06